Jessica B Rubin1, Jennifer C Lai, Amy M Shui, Samuel F Hohmann, Andrew Auerbach. 1. Division of Gastroenterology and Hepatology, Department of Medicine Division of Hospital Medicine, Department of Medicine Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA Vizient Inc. Department of Health Systems Management, Rush University, Chicago, IL.
Abstract
GOALS/ BACKGROUND: Pain is common among cirrhosis patients, particularly those hospitalized with acute illness. Managing pain in this population is challenging due to concern for adverse events and lack of guidelines for analgesic use. We sought to characterize analgesic use among inpatients with cirrhosis compared with matched noncirrhosis controls, as well as hospital-level variation in prescribing patterns. METHODS: We utilized the Vizient Clinical Database, which includes clinical and billing data from hospitalizations at >500 US academic medical centers. We identified cirrhosis patients hospitalized in 2017-2018, and a matched cohort of noncirrhosis patients. Types of analgesic given-acetaminophen (APAP), nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvants (eg, gabapentinoids, antidepressants) were defined from inpatient prescription records. Conditional logistic regression was used to associate cirrhosis diagnosis with analgesic use. RESULTS: Of 116,363 cirrhosis inpatients, 83% received at least 1 dose of an analgesic and 58% had regular inpatient analgesic use, rates that were clinically similar to noncirrhosis controls. Cirrhosis inpatients were half as likely to receive APAP (26% vs. 42%, P<0.01) or NSAIDs (3% vs. 7%, P<0.01), but were more likely to receive opioids (59% vs. 54%, P<0.01), particularly decompensated patients (60%). There was notable variation in analgesic prescribing patterns between hospitals, especially among cirrhosis patients. CONCLUSIONS: Analgesic use was common among inpatients, with similar rates among patients with and without cirrhosis. Cirrhosis patients-particularly decompensated patients-were less likely to receive APAP and NSAIDs and more likely to receive opioid analgesics. Because of lack of evidence-based guidance for management of cirrhosis patients with pain, providers may avoid nonopioid analgesics due to perceived risks and consequently may overutilize opioids in this high-risk population.
GOALS/ BACKGROUND: Pain is common among cirrhosis patients, particularly those hospitalized with acute illness. Managing pain in this population is challenging due to concern for adverse events and lack of guidelines for analgesic use. We sought to characterize analgesic use among inpatients with cirrhosis compared with matched noncirrhosis controls, as well as hospital-level variation in prescribing patterns. METHODS: We utilized the Vizient Clinical Database, which includes clinical and billing data from hospitalizations at >500 US academic medical centers. We identified cirrhosis patients hospitalized in 2017-2018, and a matched cohort of noncirrhosis patients. Types of analgesic given-acetaminophen (APAP), nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvants (eg, gabapentinoids, antidepressants) were defined from inpatient prescription records. Conditional logistic regression was used to associate cirrhosis diagnosis with analgesic use. RESULTS: Of 116,363 cirrhosis inpatients, 83% received at least 1 dose of an analgesic and 58% had regular inpatient analgesic use, rates that were clinically similar to noncirrhosis controls. Cirrhosis inpatients were half as likely to receive APAP (26% vs. 42%, P<0.01) or NSAIDs (3% vs. 7%, P<0.01), but were more likely to receive opioids (59% vs. 54%, P<0.01), particularly decompensated patients (60%). There was notable variation in analgesic prescribing patterns between hospitals, especially among cirrhosis patients. CONCLUSIONS: Analgesic use was common among inpatients, with similar rates among patients with and without cirrhosis. Cirrhosis patients-particularly decompensated patients-were less likely to receive APAP and NSAIDs and more likely to receive opioid analgesics. Because of lack of evidence-based guidance for management of cirrhosis patients with pain, providers may avoid nonopioid analgesics due to perceived risks and consequently may overutilize opioids in this high-risk population.
Authors: Elliot B Tapper; Fasiha Kanwal; Sumeet K Asrani; Chanda Ho; Nadia Ovchinsky; John Poterucha; Avegail Flores; Judith E Smith; Victor Ankoma-Sey; Bruce Luxon; Michael L Volk Journal: Hepatology Date: 2018-04-19 Impact factor: 17.425
Authors: Simona Rossi; David N Assis; Monica Awsare; Mark Brunner; Kevin Skole; Jitha Rai; Jocelyn Andrel; Steven K Herrine; Rajender K Reddy; Victor J Navarro Journal: Drug Saf Date: 2008 Impact factor: 5.606
Authors: Alok Madan; Kelly S Barth; Wendy E Balliet; Melba A Hernandez-Tejada; Jeffrey J Borckardt; Robert Malcolm; Ira Willner; David Koch; Adrian Reuben Journal: Prog Transplant Date: 2012-12 Impact factor: 1.187
Authors: Susan L Calcaterra; Traci E Yamashita; Sung-Joon Min; Angela Keniston; Joseph W Frank; Ingrid A Binswanger Journal: J Gen Intern Med Date: 2016-05 Impact factor: 5.128
Authors: Young Mi Hong; Ki Tae Yoon; Jeong Heo; Hyun Young Woo; Won Lim; Dae Seong An; Jun Hee Han; Mong Cho Journal: J Korean Med Sci Date: 2016-10 Impact factor: 2.153